409 related articles for article (PubMed ID: 29353163)
1. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
2. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
3. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
4. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
5. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
6. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
[TBL] [Abstract][Full Text] [Related]
7. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
[TBL] [Abstract][Full Text] [Related]
8. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
[TBL] [Abstract][Full Text] [Related]
9. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
10. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
11. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
[TBL] [Abstract][Full Text] [Related]
13. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.
Probst CP; Becerra AZ; Aquina CT; Tejani MA; Wexner SD; Garcia-Aguilar J; Remzi FH; Dietz DW; Monson JR; Fleming FJ;
J Am Coll Surg; 2015 Aug; 221(2):430-40. PubMed ID: 26206642
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
[TBL] [Abstract][Full Text] [Related]
15. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
[TBL] [Abstract][Full Text] [Related]
16. [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].
Müller AK; Lenschow C; Palmes D; Senninger N; Hummel R; Lindner K
Chirurg; 2015 Sep; 86(9):874-80. PubMed ID: 25662991
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
18. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
[TBL] [Abstract][Full Text] [Related]
19. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
20. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
